News

This commitment from the Gates Foundation also includes additional investments in Affinivax based on the achievement of future success-based milestones. Proceeds from the funding will be used to

ASLAN’s adoption of the industry-leading Medidata Clinical Cloud™ supports the company’s strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development

Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG") deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation-

US Patent 8,859,530 covers co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis. Formerly known as Voltarra Pharmaceuticals, Levolta’s patent claims methods for treating osteoarthritis by

Ninad Deshpanday, President of R&D at Kemwell said, "With this investment, we are bringing our customers a new service from our US facility. We will offer our clients

XIGDUO XR is a combination of two anti-hyperglycemic agents, dapagliflozin and metformin hydrochloride (HCl) extended-release in a once-daily oral tablet. It is the first and only once-daily combination

OM is a radio/chemotherapy related condition and it occurs frequently in patients undergoing head and neck cancer treatment. This condition is considered as ‘non severe’ for grades 0

The trial named AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia) is the company’s second pivotal clinical trial to assess SD-809 in tardive dyskinesia patients. The company intends to

Incruse is a long-acting muscarinic antagonist (LAMA), a type of bronchodilator which can relax airway muscles and improve airflow in and out of the lungs. Umeclidinium is the